“The Role of Clinical Pharmacology in Risk-Benefit Assessment of New Drugs”

To be presented by

Shiew-Mei Huang, PhD
(shiew-mei.huang@fda.hhs.gov)

Deputy Director
Office of Clinical Pharmacology
Office of Translational Sciences
Center for Drug Evaluation and Research (CDER)
US Food and Drug Administration (FDA)

Wednesday, June 5, 2013

6:00 – 6:20 PM – Networking; Pizza/drink
6:20 – 8:45 PM – Program
8:45 – 8:00 PM – Door-prizes drawing; Networking

Online Registration site: http://www.asq509.org/ht/d/DoSurvey/i/35817
Open to Public –
$5: non-ASQ members to cover pizza/drink cost;
Free: ASQ members, MJ-DC members, CAPA-DC members, ASCPT members, CCACC volunteers/employees, veterans, senior citizens, students, interns, residents, postdocs, FDA Commissioner’s Fellows, and current job-seekers

Location: Kelly’s Deli Conference Center, 7519 Standish Place, Rockville (Derwood, for GPS user), MD 20855

Registration Deadline: Please register by Wednesday noon, June 5, 2013.

Question: Please contact Dr. C.J. George Chang, Chair of Biomed/Biotech SIG, ASQ509; gchang2008@yahoo.com or 240-793-8425 (cell).

Driving directions: By Cars: From I-270 (N or S bound): Take Exit 9A and exit from the FIRST right exit; turn left (east) onto Shady Grove Dr.; turn right (south) onto Rockville Pike (Route 355); turn left (east) onto East Gude Dr.; turn left (north) immediately onto Crabb’s Branch Dr.; turn left (west) immediately onto Standish Place. The first building on your right side is 7519 Standish Place; open parking. The venue is on the first floor with its entrance opposite to the left side of building main entrance. By Metro trains: Off from Red Line Shady Grove Station, and take RideOn Route 59 TOWARD ROCKVILLE and get off from “Calhoun Place” stop. Standish Place is next to the Bus stop. Our venue is within 2 min of walking distance from the stop.
Summary: US Food and Drug Administration (FDA) has identified innovation in clinical evaluations as a major scientific priority area. Provisions in the recently enacted US FDA Safety and Innovation Act (FDASIA) and the reauthorized Prescription Drug User Fee Act V (PDUFA V) underscore the need for and importance of developing new approaches to streamline drug development and regulatory evaluation. This presentation provides case studies and updates to describe the efforts by the FDA’s Office of Clinical Pharmacology in its development and application of regulatory science in the risk-benefit assessment of new drugs. Key issues and challenges are identified that need to be addressed to evaluate “subset” effects (based on subtype of diseases, age, sex, race, genetics, organ dysfunctions, concomitant medications, etc.).

Presenters’ Bio: Dr. Shiew-Mei Huang is currently Deputy Director, Office of Clinical Pharmacology, Center for Drug Evaluation and Research (CDER), FDA. She received her B.S. in Pharmacy from National Taiwan University, School of Pharmacy and her Ph.D. from University of Illinois, Medical Center in Pharmacokinetics and Biopharmaceutics. Dr. Huang has 15+ years of drug development experience (Ortho pharmaceutical Corp. and Dupont-Merck Pharmaceutical Company) before joining the FDA in 1996. She chairs CDER working groups that published a draft guidance on drug interactions in 2012 and a draft guidance on pharmacokinetics in renal impairment in 2010. She is a member of the FDA Pharmacogenomics Working Group and CDER Hepatic impairment working group. She is an alternate member of the FDA Drug Safety Oversight Board.

Dr. Huang has published over 140 peer-reviewed articles and book chapters focusing on topics in clinical pharmacology, drug metabolism/interactions, and pharmacogenomics areas and has been invited to present more than 60 presentations in the past 6 years (2008-2013) at national and international meetings and workshops. She is an associate editor for a Nature journal “Clinical Pharmacology and Therapeutics” and on the editorial boards of several other journals, including Expert Review in Clinical Pharmacology, Biomarkers in Medicine, Journal of Clinical Pharmacology, Expert Opinion- Pharmacotherapy, and Pharmacogenomics. She has received many awards, including an FDA Outstanding Achievement Award, FDA Clear Communication Award, and FDA Distinguished Service Award. Dr. Huang is an AAPS Fellow (American Association of Pharmaceutical Scientists), a JSSX Fellow (Japanese Society of the Study of Xenobiotics), and a diplomate of the American Board of Clinical Pharmacology.

Dr. Huang is an Adjunct Professor at the School of Pharmacy, University of Maryland and has been a faculty member of an elective course on pharmacogenomics since 2008. She was the President (2009-2010) of the American Society for Clinical Pharmacology and Therapeutics (ASCPPT). She also served as Chair, Executive Committee, Chinese American Community Center in Delaware (1996); President, American Chinese Pharmaceutical Association (ACPA; 2000); and President, Chinese American Professionals Association of Metropolitan Washington DC (CAPA; 2002). She was the Founder of FDA White Oak Toastmasters (TM) Club and the Governor for Area 55, Division E, District 36 (2005-2006) of the International Toastmasters Club.

This Biomed/Biotech SIG event is cosponsored by the Monte Jade Science and Technology Association of Greater Washington (www.MonteJadeDC.org) and the Chinese American Professionals Association of Metropolitan Washington DC (www.capadc.org).